黑料网

In this five-part series, Dr. Dyer and Mike Gieske, MD, a primary care physician at St. Elizabeth Medical Center in Edgewood, KY, discuss a range of topics related to lung cancer screening in primary care.

Part 1: Shared Decision Making

Dr. Dyer and Dr. Gieske discuss shared decision making with the patient, how long it takes, and what resources can be used to help facilitate the conversation.

Part 2: Conversations with Patients

Dr. Dyer and Dr. Gieske discuss how to have a conversation with a patient about lung cancer screening and how to change patient intake to incorporate screening questions into your practice.

Part 3: Addressing Stigma

Dr. Dyer and Dr. Gieske focus on stigma from a healthcare professional’s point of view, including how to overcome negative feelings about patient tobacco use and how to address lung cancer screening in your practice with individuals who may not feel comfortable with the conversation.

Part 4: The False Positive Myth

Dr. Dyer continues her conversation with Dr. Gieske as they discuss the myths surrounding false positive and false negative rates.

Part 5: Low Dose CT Dosage

Dr. Dyer and Dr. Gieske wrap up their discussion on lung cancer screening in primary care with a discussion of radiation and dose exposure associated with low dose CT.

To get the pulmonologist’s perspective on lung cancer screening, Dr. Dyer speaks with Gerard Silvestri, MD, a lung cancer pulmonologist at the Medical University of South Carolina. Dr. Silvestri is a task group chair of the American Cancer Society National Lung Cancer Screening Roundtable Steering Committee.

Part 1: Role of the Pulmonologist

Dr. Dyer and Dr. Sylvestri speak about the role of the pulmonologist in lung cancer screening.

Part 2: Patient Expectations Regarding Tobacco Treatment

Dr. Dyer and Dr. Silvestri talk about what a patient can expect regarding tobacco treatment in the context of lung cancer screening in part two of this five-part conversation.

Part 3: Abnormal Exams

In part three of their five-part conversation, Dr. Dyer and Dr. Silvestri discuss what a patient should expect if their lung cancer screening CT exam is abnormal.

Part 4: Adhering to Screening Protocol Annually

Dr. Dyer continues her conversation with Dr. Silvestri on the importance of adhering to the annual screening protocol to achieve full benefit of LCS.

Part 5: The National Lung Cancer Roundtable

In the final part of their five-part conversation, Dr. Dyer and Dr. Silvestri showcase the work of the National Lung Cancer Roundtable with member organizations to advance efforts to promote lung cancer screening.

In this five-part conversation, Dr. Dyer speaks with Ella Kazerooni, MD, on radiology-related topics in lung cancer screening. Dr. Kazerooni is a professor of radiology and internal medicine and associate chief clinical officer at the University of Michigan Medical Group. She is the inaugural chair of the American Cancer Society’s National Lung Cancer Roundtable.

Part 1: Role of the Radiologist

Dr. Dyer and Dr. Kazerooni discuss the radiologist’s role in lung cancer screening in this first episode.

Part 2: Patient Expectations

Dr. Dyer continues her conversation with Dr. Kazerooni about what patients should expect when they come in for a lung cancer screening CT exam.

Part 3: Radiation Dose

Dr. Dyer and Dr. Kazerooni discuss concerns about radiation dose from lung cancer screening CT in part three of their five-part conversation.

Part 4: Abnormal Lung Screening Results

In part four of an ongoing conversation, Dr. Dyer and Dr. Kazerooni discuss what a patient should expect if their lung cancer screening CT exam is abnormal.

Part 5: The National Lung Cancer Roundtable

In the last part of their five-part conversation, Dr. Dyer and Dr. Kazerooni discuss Dr. Kazerooni’s work with the National Lung Cancer Roundtable.

In this four-part conversation, Dr. Dyer talks with Ron Simmons, a cancer survivor and advocate. Ron was initially diagnosed with stage 1 colon cancer through routine colonoscopy in 2013; his diagnosis with stage 3 lung cancer four years later was decidedly less smooth. As of 2021, Ron reports that he has no evidence of disease and was able to remove his chemotherapy port.

Part 1: Ron Simmons and His Patient Story

Dr. Debra Dyer, MD, starts her four-part conversation with Ron Simmons by asking him to share his patient story.

Part 2: Demographics of Lung Cancer Screening

Dr. Dyer and cancer survivor Ron Simmons continue their conversation with a discussion on the demographics of patients who are screened for lung cancer.

Part 3: Lung Cancer Diagnosis

Dr. Dyer and Ron Simmons discuss the patient perspective of being diagnosed with lung cancer in part three of their conversation.

Part 4: Risks Related to Lung Cancer

In the final part of their discussion, Dr. Dyer and Ron Simmons talk about the risks related to lung cancer.

Linda Dowling, RN, joins Dr. Dyer to talk about misconceptions related to nursing and lung cancer screening setting in a four-part series. Recently retired, Linda Dowling focused on on outpatient oncology and thoracic nurse navigation at Rush University Medical Center.

Part 1: Smoking Cessation and Stigma

Dr. Dyer chats with Linda Dowling about smoking cessation and stigma in the lung cancer screening setting in part one of a four-part series.

Part 2: Misconceptions of the Screening Process

Dr. Dyer and Linda Dowling discuss the myths surrounding the lung cancer screening process in part two of their conversation.

Part 3: The Patients

Dr. Dyer and nurse navigator Linda Dowling discuss what patients should know about lung cancer screening.

Part 4: Lung Cancer and COVID-19

* For the most up to date COVID-19 guidelines, please contact your local screening center.

In the final piece of their four-part discussion, Dr. Dyer and nurse navigator Linda Dowling, RN, discuss lung cancer screening amidst the COVID-19 pandemic.

Dr. Dyer joins with Dr. Patricia Rivera, MD, to discuss topics surrounding patient eligibility for lung cancer screening. Dr. Rivera is co-director of UNC-Chapel Hill’s Multidisciplinary Thoracic Oncology Program and Director of its Lung Cancer Screening Program. She is Secretary-Treasurer of the American Thoracic Society and will serve as its president in 2023. She is a member of the National Lung Cancer Roundtable and is vice-chair of the Lung Cancer in Women and the Biomarker Task Forces.

Part 1: Disparities

Dr. Dyer and Dr. Rivera discuss disparities in eligibility criteria for, access to, and implementation of lung cancer screening in part one of a five-part conversation.

Part 2: COVID-19 and Lung Cancer Screening

Dr. Dyer and Dr. Rivera discuss the impact COVID-19 has had on lung cancer screening programs across the country.

Part 3: USPSTF Guidelines

In part three of this series, Dr. Dyer and Dr. Rivera discuss the proposed USPSTF lung cancer screening guidelines.

Part 4: Biomarker Testing

For part four of their discussion, Dr. Dyer and Dr. Rivera discuss the importance of biomarker testing for patients with advanced NSCLC.

Part 5: Impact of COVID on Lung Cancer Screening

Dr. Dyer and Dr. Rivera conclude their conversation with a discussion on the impact of the COVID-19 pandemic on lung cancer screening.